Share Twitter LinkedIn Facebook Email Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains how CDK 4/6 inhibitors are being integrated into breast cancer treatment. Advertisement